Cookie Hinweis

Wir verwenden Cookies, um Ihnen ein optimales Webseiten-Erlebnis zu bieten. Dazu zählen Cookies, die für den Betrieb der Seite notwendig sind, sowie solche, die lediglich zu anonymen Statistikzwecken, für Komforteinstellungen oder zur Anzeige personalisierter Inhalte genutzt werden. Sie können selbst entscheiden, welche Kategorien Sie zulassen möchten. Bitte beachten Sie, dass auf Basis Ihrer Einstellungen womöglich nicht mehr alle Funktionalitäten der Seite zur Verfügung stehen. Weitere Informationen finden Sie in unseren Datenschutzhinweisen .

Essentiell

Diese Cookies sind für die Funktionalität unserer Website erforderlich und können nicht deaktiviert werden.

Name Webedition CMS
Zweck Dieses Cookie wird vom CMS (Content Management System) Webedition für die unverwechselbare Identifizierung eines Anwenders gesetzt. Es bietet dem Anwender bessere Bedienerführung, z.B. Speicherung von Sucheinstellungen oder Formulardaten. Typischerweise wird dieses Cookie beim Schließen des Browsers gelöscht.
Name econda
Zweck Session-Cookie für die Webanalyse Software econda. Diese läuft im Modus „Anonymisiertes Messen“.
Statistik

Diese Cookies helfen uns zu verstehen, wie Besucher mit unserer Webseite interagieren, indem Informationen anonym gesammelt und analysiert werden. Je nach Tool werden ein oder mehrere Cookies des Anbieters gesetzt.

Name econda
Zweck Measure with Visitor Cookie emos_jcvid
Externe Medien

Inhalte von externen Medienplattformen werden standardmäßig blockiert. Wenn Cookies von externen Medien akzeptiert werden, bedarf der Zugriff auf diese Inhalte keiner manuellen Zustimmung mehr.

Name YouTube
Zweck Zeige YouTube Inhalte
Name Twitter
Zweck Twitter Feeds aktivieren

Selected Publications

CUP - Carcinoma of Unknown Primary

Westphalen CB, Federer-Gsponer J, Pauli C, Karapetyan AR, Chalabi N, Durán-Pacheco G, Beringer A, Bochtler T, Cook N, Höglander E, Jin DX, Losa F, Mileshkin L, Moch H, Ross JS, Sokol ES, Tothill RW, Krämer A: Baseline mutational profiles of patients with carcinoma of unknown primary origin enrolled in the CUPISCO study. ESMO Open 8(6): 102035, 2023.

Pouyiourou M, Kraft BN, Wohlfromm T, Stahl M, Kubuschok B, Löffler H, Hacker UT, Hübner G, Weiss L, Bitzer M, Ernst T, Schütt P, Hielscher T, Delorme S, Kirchner M, Kazdal D, Ball M, Kluck K, Stenzinger A, Bochtler T, Krämer A: Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial. Nature Communications 14(1): 6761, 2023.

Pouyiourou M, Bochtler T, Coith C, Wikman H, Kraft B, Hielscher T, Stenzinger A, Riethdorf S, Pantel K, Krämer A: Frequency and prognostic value of circulating tumor cells in cancer of unknown primary. Clinical Chemistry (in press), 2023.

Le Tourneau C, Andre F, Helland A, Mileshkin L, Minnaard W, Schiel A, Tasken K, Thomas DM, Veronese ML, Duran-Pacheco G, Leyens L, Rufibach K, Thomas M, Krämer A. Modified study designs to expand treatment options in personalised oncology: a multistakeholder view. European Journal of Cancer 194: 113278, 2023.

Bochtler T, Christopoulos P, Schlamp K, Winkler F, Krämer A. Management of a Pregnant ALK-Positive Lung Cancer Patient With Alectinib-Induced Pneumonitis and Bilateral Globus Pallidus Necrosis Postpartum. Clinical Lung Cancer (Online ahead of print) 2023.

Krämer A, Bochtler T, Pauli C, Baciarello G, Delorme S, Hemminki K, Mileshkin L, Moch H, Oien K, Olivier T, Patrikidou A, Wasan H, Zarkavelis G, Pentheroudakis G, Fizazi K, on behalf of the ESMO Guidelines Committee: Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology 34: 228-246, 2023.

Mileshkin L, Bochtler T, Gatta G, Kurzrock R, Beringer A, Müller-Ohldach M, Surinach A, Perret C, Thomas M, Gondos A, Krämer A: Cancer-of-unknown-primary-origin: A SEER – Medicare study of patterns of care and outcomes among elderly patients in clinical practice. Cancers 14: 2905, 2022.

Bochtler T, Wohlfromm T, Hielscher T, Stichel D, Pouyiourou M, Kraft B, Neumann O, Endris V, von Deimling A, Stenzinger A, Krämer A: Prognostic impact of copy number alterations and tumor mutational burden in carcinoma of unknown primary. Genes Chromosomes Cancer 61: 551-560, 2022.

Pouyiourou M, Wohlfromm T, Kraft B, Hielscher T, Stichel D, von Deimling A, Delorme S, Endris V, Neumann O, Stenzinger A, Krämer A, Bochtler T: Local ablative treatment with surgery and/or radiotherapy in single-site and oligometastatic carcinoma of unknown primary (CUP). European Journal of Cancer 157: 179-189, 2021.

Pauli C, Bochtler T, Mileshkin L, Baciarello G, Losa F, Ross J, Pentheroudakis G, Zarkavelis G, Yalcin S, Özgüroğlu M, Beringer A, Scarato J, Mueller-Ohldach M, Thomas M, Moch H, Krämer A: A challenging task – Identifying patients with cancer of unknown primary (CUP) according to ESMO guidelines: the CUPISCO trial experience. Oncologist 26: e769-e779, 2021.

Folprecht G, Trautmann K, Stein A, Hübner G, Stahl M, Kasper S, Kretzschmar A, Köhne CH, Grünwald V, Hofheinz R, Schütte K, Löffler H, Bokemeyer C, Krämer A, Arbeitsgemeinschaft Internistische Onkologie (AIO) - CUP group: Adding cetuximab to paclitaxel and carboplatin for first-line treatment of carcinoma of unknown primary (CUP): results of the phase II PACET-CUP trial. British Journal of Cancer 124: 721-727, 2021.

Ross JS, Sokol ES, Moch H, Mileshkin L, Baciarello G, Losa F, Beringer A, Thomas M, Elvin J, Ngo N, Jin DX, Krämer A: Comprehensive genomic profiling of carcinoma-of-unknown-primary-origin: retrospective molecular classification considering the CUPISCO study design. Oncologist 26: e394-e402, 2021.

Bochtler T, Reiling A, Endris V, Hielscher T, Volckmar AL, Neumann O, et al.: Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary. International Journal of Cancer 146: 3053–3064, 2020.

Bochtler T, Endris V, Leichsenring J, Reiling A, Neumann O, Volckmar AL, et al.: Comparative genetic profiling aids diagnosis and clinical decision making in challenging cases of CUP syndrome. International Journal of Cancer 145: 2963–2973, 2019.

Kirchner M, Neumann O, Volckmar AL, Stögbauer F, Allgäuer M, Kazdal D, et al.: RNA-Based Detection of Gene Fusions in Formalin-Fixed and Paraffin-Embedded Solid Cancer Samples. Cancers 11: 1309, 2019.

Bochtler T, Endris V, Reiling A, Leichsenring J, Schweiger MR Klein S, et al.: Integrated Histogenetic Analysis Reveals BAP1-Mutated Epithelioid Mesothelioma in a Patient With Cancer of Unknown Primary. Journal of the National Comprehensive Cancer Network 16: 677–682, 2018.

Hemminki K, Chen B, Kumar A, Melander O, Manjer J, Hallmans G, et al.: Germline genetics of cancer of unknown primary (CUP) and its specific subtypes. Oncotarget 7: 22140–22149, 2016.

Löffler H, Pfarr N, Kriegsmann M, Endris V, Hielscher T, Lohneis P, et al.: Molecular driver alterations and their clinical relevance in cancer of unknown primary site. Oncotarget 7: 44322–44329, 2016.

CIN - Chromosomal Instability

Köhrer S, Dittrich T, Schorb M, Weinhold N, Haberbosch I, Bormel M, Pajor G, Goldschmidt H, Müller-Tidow C, Raab MS, John L, Seckinger A, Brobeil A, Dreger P, Tornoczky T, Pajor L, Hegenbart U, Schönland S, Schwab Y, Krämer A. High-throughput electron tomography identifies centriole over-elongation as an early event in plasma cell disorders. Leukemia (Online ahead of print) 2023.

Köhrer S, Dittrich T, Schorb M, Haberbosch I, Schwab Y, Krämer A. Protocol for high-throughput electron tomography exemplified on centrioles in primary human plasma cells. STAR Protocols 4(3): 102373, 2023.

Dittrich T, Köhrer S, Schorb M, Haberbosch I, Börmel M, Goldschmidt H, Müller-Tidow C, Raab MS, Hegenbart U, Schönland SO, Schwab Y, Krämer A: A high-throughput electron tomography workflow reveals over-elongated centrioles in relapsed-refractory multiple myeloma. Cell Reports Methods 2: 100322, 2022.

Vit G, Hirth A, Neugebauer N, Kraft B, Sigismondo G, Cazzola A, Tessmer C, Duro J, Krijgsveld J, Hofmann I, Berger M, Klüter H, Niehrs C, Nilsson J, Krämer A: Human SLFN5 and its Xenopus Laevis Ortholog Regulate Entry into Mitosis and Oocyte Meiotic Resumption. Cell Death Discovery 8: 484, 2022.

Cazzola A, Schlegel C, Jansen I, Bochtler T, Jauch A, Krämer A: TP53 deficiency permits chromosome abnormalities and karyotype heterogeneity in acute myeloid leukemia. Leukemia 33: 2619–2627, 2019.

Kraft B, Lombard J, Kirsch M, Wuchter P, Bugert P, Hielscher T, et al.: SMC3 protein levels impact on karyotype and outcome in acute myeloid leukemia. Leukemia 33: 795–799, 2019.

Bochtler T, Kartal-Kaess M, Granzow M, Hielscher T, Cosenza MR, Herold-Mende C, et al.: Micronucleus formation in human cancer cells is biased by chromosome size. Genes Chromosomes and Cancer 58: 392–395, 2019.

Bochtler T, Merz M, Hielscher T, Granzow M, Hoffmann K, Krämer A, et al.: Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma. Blood Advances 2: 2607–2618, 2018.

Cosenza MR, Cazzola A, Rossberg A, Schieber NL, Konotop G, Bausch E, et al.: Asymmetric Centriole Numbers at Spindle Poles Cause Chromosome Missegregation in Cancer. Cell Reports 20: 1906–1920, 2017.

Bochtler T, Granzow M, Stölzel F, Kunz C, Mohr B, Kartal-Kaess M, et al.: Marker chromosomes can arise from chromothripsis and predict adverse prognosis in acute myeloid leukemia. Blood 129: 1333–1342, 2017.

Konotop G, Bausch E, Nagai T, Turchinovich A, Becker N, Benner A, et al.: Pharmacological Inhibition of Centrosome Clustering by Slingshot-Mediated Cofilin Activation and Actin Cortex Destabilization. Cancer Research 76: 6690–6700, 2016.

Daly OM, Gaboriau D, Karakaya K, King S, Dantas TJ, Lalor P, et al.: CEP164-null cells generated by genome editing show a ciliation defect with intact DNA repair capacity. Journal of Cell Science 129: 1769–1774, 2016.

Stölzel F, Mohr B, Kramer M, Oelschlägel U, Bochtler T, Berdel WE, et al.: Karyotype complexity and prognosis in acute myeloid leukemia. Blood Cancer Journal 6, e386, 2016.

Alsara M, Löffler H, Fechter A, Bartek J, Krämer A: Cep63 recruits cdk1 to the centrosome-letter. Cancer Research 75: 777–778, 2015.

Bochtler T, Fröhling S, Krämer A: Role of chromosomal aberrations in clonal diversity and progression of acute myeloid leukemia. Leukemia 29: 1243–1252, 2015.

Bochtler T, Stölzel F, Heilig CE, Kunz C, Mohr B, Jauch A, et al.: Clonal heterogeneity as detected by metaphase karyotyping is an indicator of poor prognosis in acute myeloid leukemia. Journal of Clinical Oncology 31: 3898–3905, 2013.

Mardin BR, Isokane M, Cosenza MR, Krämer A, Ellenberg J, Fry AM Schiebel E: EGF-induced centrosome separation promotes mitotic progression and cell survival. Developmental Cell 25: 229–240, 2013.

Löffler H, Fechter A, Liu FY, Poppelreuther S, Krämer A: DNA damage-induced centrosome amplification occurs via excessive formation of centriolar satellites. Oncogene 32: 2963–2972, 2013.

Vulprecht J, David A, Tibelius A, Castiel A, Konotop G, Liu FY, et al.: STIL is required for centriole duplication in human cells. Journal of Cell Science 125: 1353–1362, 2012.

Raab MS, Breitkreutz I, Anderhub S, Rønnest MH, Leber B, Larsen TO, et al.: GF-15, a novel inhibitor of centrosomal clustering, suppresses tumor cell growth in vitro and in vivo. Cancer Research 72: 5374–5385, 2012.

Stein S, Ott MG, Schultze-Strasser S, Jauch A, Burwinkel B, Kinner A, et al.: Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nature Medicine 16: 198–204, 2010.

Leber B, Maier B, Fuchs F, Chi J, Riffel P, Anderhub S, et al.: Proteins required for centrosome clustering in cancer cells. Science Translational Medicine 2: 33ra38, 2010.

Tibelius A, Marhold J, Zentgraf H, Heilig CE, Neitzel H Ducommun B, et al.: Microcephalin and pericentrin regulate mitotic entry via centrosome-associated Chk1. Journal of Cell Biology 185: 1149–1157, 2009.

Rebacz B, Larsen TO, Clausen MH, Rønnest MH, Löffler H, Ho AD, Krämer A: Identification of griseofulvin as an inhibitor of centrosomal clustering in a phenotype-based screen. Cancer Research 67: 6342–6350, 2007.

Bartkova J, Horejsí Z, Koed K, Krämer A, Tort F, Zieger K, et al.: DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434: 864–870, 2005.

Krämer A, Mailand N, Lukas C, Syljuåsen RG, Wilkinson C, Nigg EA, et al.: Centrosome-associated Chk1 prevents premature activation of cyclin-B-Cdk1 kinase. Nature Cell Biology 6: 884–891, 2004.

Neben K, Giesecke C, Schweizer S, Ho AD, Krämer A: Centrosome aberrations in acute myeloid leukemia are correlated with cytogenetic risk profile. Blood 101: 289–291, 2003.

MM - Multiple Myeloma

John L, Poos AM, Brobeil A, Schinke C, Huhn S, Prokoph N, Lutz R, Wagner B, Zangari M, Tirier SM, Mallm JP, Schumacher S, Vonficht D, Solé-Boldo L, Quick S, Steiger S, Przybilla MJ, Bauer K, Baumann A, Hemmer S, Rehnitz C, Lückerath C, Sachpekidis C, Mechtersheimer G, Haberkorn U, Dimitrakopoulou-Strauss A, Reichert P, Barlogie B, Müller-Tidow C, Goldschmidt H, Hillengass J, Rasche L, Haas SF, van Rhee F, Rippe K, Raab MS, Sauer S, Weinhold N. Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level. Nature Communications 14(1): 5011, 2023.

Poos AM, Prokoph N, Przybilla MJ, Mallm JP, Steiger S, Seufert I, John L, Tirier SM, Bauer K, Baumann A, Rohleder J, Munawar U, Rasche L, Kortüm KM, Giesen N, Reichert P, Huhn S, Müller-Tidow C, Goldschmidt H, Stegle O, Raab MS, Rippe K, Weinhold N. Resolving therapy resistance mechanisms in multiple myeloma by multi-omics subclone analysis. Blood (Epub ahead of print) 2023.

Raab MS, Cohen YC, Schjesvold F, Aardalen K, Oka A, Spencer A, Wermke M, Souza AD, Kaufman JL, et al.: Preclinical discovery and initial clinical data of WVT078, a BCMA × CD3 bispecific antibody. Leukemia 37(6):1349-1360, 2023.

Friedrich MJ, Neri P, Kehl N, Michel J, Steiger S, Kilian M, Leblay N, Maity R, Sankowski R, Lee H, Barakat E, Ahn S, Weinhold N, Rippe K, Bunse L, Platten M, Goldschmidt H, Müller-Tidow C, Raab MS, Bahlis NJ. The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients. Cancer Cell 41(4):711-725, 2023.

Giesen N, Chatterjee M, Scheid C, Poos AM, Besemer B, Miah K, Benner A, Becker N, Moehler T, Metzler I, Khandanpour C, Seidel-Glaetzer A, Trautmann-Grill K, Kortüm KM, Müller-Tidow C, Mechtersheimer G, Goeppert B, Stenzinger A, Weinhold N, Goldschmidt H, Weisel KC, Raab MS. A phase II clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myeloma. Blood 141(14):1685-1690, 2023.

Giesen N, Paramasivam N, Toprak UH, Huebschmann D, Xu J, Uhrig S, Samur M, Bähr S, Fröhlich M, Mughal SS, Mai EK, Jauch A, Müller-Tidow C, Brors B, Munshi N, Goldschmidt H, Weinhold N, Schlesner M, Raab MS. Comprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilities. Haematologica 107(8): 1891-1901, 2022.

Tirier SM, Mallm JP, Steiger S, Poos AM, Awwad MHS, Giesen N, Casiraghi N, Susak H, et al.: Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomics. Nature Communications 12(1):6960, 2021.

Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, Leleu X, LeBlanc R, Suzuki K, Raab MS, et al.: Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma. The New England Journal of Medicine 379(19):1811-1822, 2018.

to top
powered by webEdition CMS